What are the main changes in the 2025 PONV consensus guidelines?

The Fifth Consensus Guidelines for PONV, published November 14, 2025 in Anesthesia & Analgesia (Gan TJ et al., DOI: 10.1213/ANE.0000000000007816), represent the first update since 2020. The biggest shift is endorsing near-universal multimodal prophylaxis — including for patients previously considered low risk — and explicitly highlighting post-discharge nausea and vomiting (PDNV) as a major underaddressed concern for ASC patients. The guidelines also continue to endorse the Apfel simplified risk score for adult stratification while acknowledging that most adult surgical patients have at least one risk factor.

What is the Apfel score and how is it used in plastic surgery patients?

The Apfel simplified risk score assigns one point each for: female sex, non-smoking status, history of PONV or motion sickness, and anticipated postoperative opioid use. Scores of 0 indicate low risk; 1–2 medium risk; 3 or more high risk. The plastic surgery population — predominantly female, frequently non-smoking, and often requiring opioids — tends to score 2–4, placing most patients in the medium-to-high risk range where aggressive multimodal prophylaxis is warranted. The Fifth Consensus Guidelines reaffirm the Apfel score as the standard adult stratification tool.

How does untreated PONV affect outpatient surgery centers financially?

Untreated PONV affects approximately 30% of all general anesthesia patients and up to 70–80% of high-risk cohorts, making it one of the leading causes of unexpected admission and extended PACU stays after outpatient surgery. For ASCs managing cash-pay cosmetic cases that bill $12,000–$25,000, unplanned admissions and patient dissatisfaction represent direct revenue risk, reputation damage, and OR schedule disruption. Systematic multimodal prophylaxis, when applied consistently, can reduce institutional PONV rates from roughly 50% to below 20%.

What multimodal PONV prophylaxis regimen should CRNAs use for high-risk patients?

The Fifth Consensus Guidelines endorse combination antiemetic regimens targeting multiple receptor mechanisms. A commonly used multimodal approach for high-risk patients includes dexamethasone at induction, a 5-HT3 antagonist (e.g., ondansetron) at closure, preoperative transdermal scopolamine, and an NK1 receptor antagonist (e.g., aprepitant 40 mg PO or an injectable formulation) for extended PDNV coverage. Rescue therapy should use an agent from a different drug class than what was used for prophylaxis. Always consult the full guideline text and your facility's formulary for individualized decision-making.

Do the 2025 PONV guidelines change the standard of care for ASC anesthesia protocols?

Yes. The Fifth Consensus Guidelines, published November 14, 2025, represent the current consensus standard of care and should prompt ASCs to audit and update their written antiemetic protocols accordingly. The shift toward near-universal multimodal prophylaxis — including patients previously classified as low risk — and the explicit attention to PDNV are both significant operational changes for outpatient facilities. Protocols that have not been updated since before November 2025 may no longer reflect the published standard.

PONV Guidelines 2025: What Every ASC & CRNA Must Do Now

The Fifth Consensus Guidelines just expanded multimodal prophylaxis to nearly every surgical patient — here's what that means for your ASC, your formulary, and your patients.

The Case the Old Playbook Misses

Consider a case type every cosmetic anesthesia provider will recognize. A 38-year-old, healthy, a non-smoker. Bilateral breast augmentation, total anesthesia time under two hours. Apfel score of 2 — technically "medium risk" by the old thinking. She gets ondansetron 4 mg at closure. Standard stuff. By the time she hits the PACU she's vomiting every 20 minutes, her blood pressure is climbing from the retching, and her surgeon is standing at the nurses' station wanting answers.

We kept her three hours past her scheduled discharge. The surgeon had two more cases stacking up. The patient was miserable, her husband was anxious, and the whole day got compressed in a way that nobody bills for — not the extra nursing time, not the delayed room turnover, not the surgeon's goodwill with a cash-pay patient who spent $14,000 expecting to go home feeling good.

That story isn't unusual. Postoperative nausea and vomiting affects roughly 30% of all general anesthesia patients when left untreated — and that number climbs to 70–80% in high-risk cohorts, which includes a significant portion of the cosmetic and plastic surgery population. Those aren't abstract statistics. That's your PACU on a Tuesday.

Now, the Fifth Consensus Guidelines have arrived — and they're asking us to do better. All of us.

What the Fifth Consensus Guidelines Actually Say

The Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (Gan TJ et al., Anesthesia & Analgesia, November 14, 2025, DOI: 10.1213/ANE.0000000000007816) represent the first major update to PONV management since 2020. This wasn't a minor revision. An international, multidisciplinary panel convened, reviewed the literature, and came back with recommendations that should prompt every ASC medical director and every CRNA running their own anesthesia protocol to sit down and audit what they're currently doing.

The headline shift: near-universal multimodal prophylaxis. Not just for your Apfel-4 patients. Not just for the laparoscopic cholecystectomy in a middle-aged woman with a history of motion sickness. For nearly everyone.

According to the Drug Information Group at the University of Illinois Chicago (May 2026), the Fifth Edition "proposes combination antiemetic regimens for prophylaxis AND recommends extending prophylaxis to patients previously considered low risk." Read that sentence twice. The category of "low risk, no prophylaxis needed" has effectively been collapsed.

The full text in Anesthesia & Analgesia reaffirms the Apfel simplified risk score — female sex, non-smoking status, history of PONV or motion sickness, and anticipated postoperative opioid use — as the standard adult stratification tool. Zero factors equals low risk; one to two factors equals medium risk; three or more equals high risk. But the guidelines are candid about something that practicing CRNAs have known for a long time: most adult surgical patients will have at least one PONV risk factor. The "true low-risk" patient is rarer than the score implies.

Why Risk-Only Algorithms Have Been Failing Us

Here's the honest truth about risk-stratified PONV protocols in the real world: they sound great in a guideline and they fall apart at 7:15 AM when you're doing your first of four cases and nobody has pulled up the Apfel calculator. Across real-world facilities, adherence to risk-based algorithms is inconsistent at best.

The new guidelines acknowledge this directly. The executive summary from Anesthesia Experts highlights three reasons the field is moving toward more liberal prophylaxis: (1) imperfect risk capture by scoring tools, (2) inconsistent real-world adherence to risk-based algorithms, and (3) the favorable safety profile of modern antiemetics. When your intervention is safe and cheap and the consequence of under-treating is significant, the calculus tips toward treat-everyone.

And the data on what systematic application can actually achieve is compelling. NYSORA's PONV review cites evidence that systematic use of validated risk-stratification tools combined with multimodal prophylaxis can reduce institutional PONV rates from approximately 50% down to below 20%. That's not a marginal improvement — that's a transformation of your PACU culture.

The gap between 50% and 20% is where unexpected admissions live. Where patient satisfaction scores crater. Where a $20,000 cosmetic case turns into a liability conversation. For private-practice plastic surgeons running a high-volume cash-pay ASC, that math is not abstract.

The PDNV Problem: What Happens After They Leave Your Building

One of the most important expansions in the Fifth Consensus Guidelines is the explicit emphasis on post-discharge nausea and vomiting (PDNV) — what happens after your patient walks out the door, gets into the car, and arrives home. This is where the ASC model has a structural vulnerability that inpatient facilities don't share.

Per Heron Therapeutics' December 2025 announcement regarding inclusion in the Fifth Consensus Guidelines, the guidelines specifically emphasize long-acting antiemetic strategies that extend protection beyond the PACU — directly addressing the PDNV risk that outpatient and ASC patients face when they're discharged within hours of anesthesia. The standard ondansetron 4 mg at closure has a half-life of roughly three to five hours. If your patient's nausea peaks at hour six at home, that dose is already gone.

This is where agents like NK1 receptor antagonists deserve a closer look. Aprepitant (APONVIE injectable formulation) and oral fosaprepitant have longer durations of action that are well-suited to the PDNV window. The guidelines' acknowledgment of these agents as part of a multimodal approach isn't just academic — it's a formulary conversation your ASC pharmacy committee needs to have right now.

A guideline-concordant multimodal baseline for high-risk cosmetic cases looks like this: dexamethasone 8 mg at induction, ondansetron 4 mg at closure, scopolamine transdermal patch placed preoperatively, and — for Apfel 3–4 patients — aprepitant 40 mg PO the morning of surgery or an NK1 injectable agent intraoperatively. That's four different receptor mechanisms working in parallel. The incremental drug cost is well under $50. The PACU time saved, and the patient satisfaction preserved, is worth many multiples of that on a $15,000 cash case.

What Your ASC Protocol Needs to Change — Right Now

The operational implications of these guidelines deserve to be stated directly for anyone running a surgery center or managing anesthesia in one.

First: audit your current protocol against the new standard. If your written antiemetic protocol was last updated before November 2025, it is no longer consistent with current consensus guidelines. That matters for accreditation. It matters for your defense if something goes wrong. Pull the protocol, compare it to the Fifth Consensus recommendations, and document the update with a date and the responsible clinician's signature.

Second: make Apfel scoring automatic, not optional. The Apfel score only works if it's calculated on every patient, every time, before the case starts — not in your head at the scrub sink. This means building it into your preoperative workflow. At the facilities where we use VeriOp.ai, the Apfel score is calculated automatically from the patient's preoperative screening data — sex, smoking history, PONV/motion sickness history, anticipated opioid use — and surfaces in the anesthesia provider's workflow before the patient ever reaches the OR. That's the kind of systematic application that drives PONV rates from 50% to below 20%.

Third: expand your formulary for PDNV coverage. Add at least one long-acting antiemetic option — NK1 antagonist, transdermal scopolamine, or extended-release formulations — to your ASC formulary and build it into your high-risk order sets. If patients are going home in three hours, your antiemetic strategy needs to follow them home.

Fourth: train your entire PACU team on rescue protocols. The Fifth Consensus Guidelines don't just address prophylaxis — they also call for a disciplined rescue strategy. When prophylaxis fails (and it will, occasionally), the rescue agent should be from a different drug class than what was used for prophylaxis. Giving another dose of ondansetron to a patient who already got ondansetron at closure is not evidence-based rescue. It's habit.

The Plastic Surgery Population Is Your Highest-Stakes Cohort

It's worth being specific about why this matters so acutely for plastic surgery and cosmetic procedure ASCs, because the risk profile of this patient population and the financial model of these practices create a particular set of pressures.

Look at the Apfel risk factors against your typical cosmetic patient: overwhelmingly female, frequently non-smokers, often with histories of motion sickness (it comes up in consults more than you'd think), and — even with regional blocks and multimodal analgesia — often requiring some opioids in the perioperative period. Three-factor Apfel scores are the rule, not the exception, in a cosmetic surgery population. The 70–80% untreated PONV rate in high-risk cohorts isn't theoretical for these patients. It's the default outcome if you don't intervene aggressively.

And the financial stakes are real. A cash-pay abdominoplasty or mommy makeover bills $12,000 to $25,000. The patient is not a covered life in a fee-for-service system where complications are just a different billing code. She is a consumer who made a deliberate choice to spend significant money, took time off work, arranged childcare, and expected a positive experience. An unplanned overnight admission — or even just a miserable six hours in your PACU — is a reputation event. It is a Google review. In a referral-driven practice, it compounds.

The good news is that getting this right is entirely achievable. The clinical validation data we've built around VeriOp.ai supports systematic preoperative risk identification — including PONV risk factors — as part of a structured AI-assisted intake workflow designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act. Identifying a patient's Apfel score before the day of surgery means your anesthesia team isn't making prophylaxis decisions cold at 6:45 AM. It means the plan is in the chart before the patient arrives.

The Bottom Line for CRNAs and ASC Leaders

The Fifth Consensus Guidelines don't ask us to do something exotic or expensive. They ask us to do something systematic. They ask us to stop pretending that an Apfel score of 1 is a reason to under-treat, to stop relying on single-agent prophylaxis for patients we already know are high risk, and to stop letting PDNV be someone else's problem once the patient leaves our building.

The international panel that produced these guidelines — supported in part by unrestricted educational grants from the American Society for Enhanced Recovery — spent years reviewing evidence to give us a clear direction. Near-universal multimodal prophylaxis. Long-acting agents for PDNV. Disciplined rescue from a different drug class. Systematic risk scoring on every patient.

That is the new standard of care. Not a suggestion. Not a best practice aspiration. The standard. And the gap between knowing the standard and operationalizing it in a busy ASC is where patient outcomes actually live.

Update your protocol. Audit your formulary. Make the Apfel score automatic. And if you want a preoperative workflow that does the risk stratification work before your team ever sees the patient in the OR, that's exactly what VeriOp.ai was built to support.

Your patients — and your PACU nurses — will thank you.